Patent Blocks Zydus After Landmark US Approval For Dapagliflozin

With more than a dozen ANDA sponsors chasing AstraZeneca’s Farxiga SGLT2 inhibitor, Zydus Cadila has scooped the first FDA approval for a generic version of the game-changing type 2 diabetes drug. However, a key US patent stands in its way.